Novartis Investigative Site — Seoul

Public research footprint of Novartis Investigative Site, compiled from the ClinicalTrials.gov public registry.

382

Registered studies

Active

Recruiting now

232

Completed

Stopped or withdrawn

Most-studied conditions

B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma… · Advanced Solid Tumors Harboring the KRAS G12C Mutation · Extensive Stage Small Cell Lung Cancer · Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive

Recently updated registry entries

NCT07681271 — A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib… (Recruiting)
NCT05142696 — A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With… (Active Not Recruiting)
NCT05274425 — A 24-week rPMS Study in Real-world Setting for Enerzair (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Novartis Investigative Site?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 05, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.